A Phase II Study Integrating a Single-Blind Safety Phase with a Double-Blind, Placebo-Controlled Randomized Phase, Assessing Single-Dose Intramuscular or Intranasal Administration to Evaluate the Safety and Immunogenicity of the Recombinant Vaccine Against COVID-19 (AVX/COVID-12 “Patria”) Based on an Active Newcastle Disease Viral Vector as a Heterologous Booster in Subjects with Evidence of Previous Immunity to SARS-CoV-2

Study design

A phase II study (ClinicalTrials.gov #NCT05205746) was conducted to assess the safety phase under single-blind conditions, followed by randomized, double-blind, placebo-controlled, single-dose administration via IM or IN routes, in subjects with evidence of prior immunity to SARS-CoV-2. This was followed by an assessment phase to evaluate the booster response, involving an IM dose of the COVID-19 vaccine (recombinant AZ/ChAdOx-1-S) in subjects originally randomized to the placebo arm.

The protocol was formulated by iLS Clinical Research, S.C. in collaboration with the Mexican Institute for Social Security (IMSS) and Laboratorio Avi-Mex, S.A. de C.V. (Avimex®), which was the sponsor. Approval for the study was granted by the Federal Commission for the Protection against Sanitary Risks (COFEPRIS) in Mexico, assigned the number RNEC2021-AVXSARSCoV2VAC002. Ethics approval was obtained from the institutional ethics committee at each research site participating in the study. The research was conducted in complete compliance with Mexican regulations and by the principles outlined in the Declaration of Helsinki and Good Clinical Practice. Immunological assay samples were processed at the National Institute for Respiratory Diseases (INER) in Mexico City.

Study groups

The study groups included adults aged 18 years or older of both genders who signed informed consent and had not experienced respiratory issues in the 21 days preceding the administration of the single dose. Participants committed to maintaining appropriate preventive measures to avoid SARS-CoV-2 infection throughout their study participation, particularly during the initial 14 days following the baseline visit. Additionally, eligibility criteria involved having detectable anti-spike IgG titers in serum during the screening visit, with titers levels less than 1,200 U/mL measured in a chemiluminescence test. Furthermore, participants were required to provide evidence of vaccination, with a minimum of 4 months having passed since the last vaccination. Due to the nature of the study, recruited subjects were enrolled in one of three subgroups based on the vaccine technology used during the primary immunization against SARS-CoV-2: subjects with a history of prior immunization with vaccines based on adenoviral technology, inactivated virus, or mRNA technology.

The exclusion criteria encompassed hypersensitivity or allergy to any component of the vaccine, a history of severe anaphylactic reactions, a history of seizures, uncontrolled chronic diseases, chronic conditions requiring treatment with immunosuppressive agents or immune response modulators (e.g., systemic corticosteroids, cyclosporine, rituximab, among others), the development of oncological diseases, active participation in or involvement within the last three months in any other clinical or experimental intervention study, use of any drug or herbal supplement in the 30 days preceding the screening evaluation, or alternative medicine (e.g., chlorine dioxide, etc.) aimed at treating or preventing complications or SARS-CoV-2 infection, or any other condition, fever at the time of the screening visit, and having received any vaccine (experimental or approved) in the 60 days prior to the screening visit, except for the influenza vaccine. Exclusion criteria also included having received a blood or blood component transfusion, or being a plasma donor within the 4 months prior to the screening visit, undergoing dialysis or hemodialysis procedures in the last year before the screening visit, working on poultry or gamecock farms, and having a history of substance abuse problems that, in the investigator’s judgment, could interfere with the subject’s ability to comply adequately with the protocol guidelines.

The randomization of volunteers was conducted using a computer-based random assignment system, ensuring blinding throughout the study. Upon signing the informed consent form, each participant received a patient number, encoding all their information in a pseudo-anonymized manner during data collection and becoming fully anonymized during the analysis.

The stratification for subject randomization was generated as follows:

Safety phase: Involved single-blinded assignment (blinded to the research subject) to the arm receiving the AVX/COVID-12 vaccine for the first three subjects of each specific vaccine recruited in each branch, IM and IN. For this purpose, eight blocks of six vaccines were generated, and to each block, three subjects with the AVX/COVID-12 vaccine and three subjects with placebo were randomly assigned.

Double-blind, placebo-controlled randomized phase: subjects with the corresponding vaccination history were randomized to receive a placebo or the AVX/COVID-12 vaccine in either of the two administration modalities (IM or IN). Starting from block 9, blocks of 4 were generated, and each block was randomly assigned 1 subject with IM AVX/COVID-12 vaccine, 1 subject with IN AVX/COVID-12 vaccine, 1 subject with IM placebo, and 1 subject with IN placebo.

After 14 days, following the administration of the AVX/COVID-12 vaccine or placebo, the blinding was revealed for subjects who received a placebo. These subjects received an additional dose of the COVID-19 vaccine (AZ/ChAdOx-1-S) IM.

AVX/COVID-12 vaccine preparation

The AVX/COVID-12 vaccine was manufactured in a purpose-built good manufacturing practice (GMP) facility. The recombinant virus was cultivated in 10-day-old specific-pathogen-free (SPF) chicken embryos through inoculation via the allantoic cavity with 10^3.3 EID50/0.1 mL of the production seed. The embryos were incubated for a period of 72 hours (h) at an average temperature of 37 °C and a relative humidity range of 60% to 70%. After this period, the embryos were refrigerated for at least 12 h to sacrifice them. Harvesting of the allantoic fluid (AF) was conducted under aseptic conditions using a vacuum. The AF was clarified through filters with a pore size of 0.8 to 8.0 μm, concentrated by a factor of 10X in 300-kDa cassettes, and subjected to diafiltration in 20 volumes of phosphate-buffered saline (PBS). The AF was stored frozen at −70 °C. The AF yielded a titer of 10^8.67 EID50/mL, from which the frozen active vaccines were prepared. The corresponding volumes of purified AF were aseptically mixed with the stabilizer trehalose, monobasic potassium phosphate, dibasic sodium phosphate and monosodium glutamate and homogeneously mixed for 5 minutes using a Teflon bar and a magnetic stirrer. Finally, they were packed in high-density polyethylene bottles. The vaccines were stored at −80 °C.

Safety

Safety was assessed by comparing adverse events (AEs) between placebo and AVX/COVID-12 vaccine groups, considering their severity and relationship to the intervention. While all participants completed the same visits, those assigned to specific groups underwent additional sample collections during visits corresponding to days 0, 14, 42, 90, 180 and 365 of the study. The primary endpoints in the phase II aspects of this trial included solicited local and systemic AEs. The classification of potential AEs and their association with vaccine exposure followed a two-period analysis. The first period included the initial seven days following vaccination, during which AEs were deemed related to the vaccine components. Conversely, reactions occurring after seven days, typically in response to the development of an immune response, constituted the second period of analysis (13).

Sample collection

Venous blood samples were obtained from participants during scheduled site visits for serology tests and cellular response assessments. Using standard phlebotomy procedures, the samples were collected into two sodium heparin tubes and one separator tube (SST BD vacutainer tubes, Franklin Lakes, NJ, USA). Following collection, the samples were transported at room temperature to the INER for immediate processing. All blood samples and products were handled in a BSL-2 laboratory, using appropriate personal protective equipment and safety precautions, adhering to processing protocols approved by the Institutional Biosafety Committee. Peripheral blood samples from each volunteer were centrifuged at 2,260 x g at room-temperature for 10 minutes and transported to a biological safety cabinet. Then, for each sample, the serum was recovered, divided into six aliquots of 200 μL, stored in pre-labeled 1.5 mL cryovials according to the established procedure, and frozen at -20 °C until use. One aliquot of serum was thawed for each antibody determination, and the remaining portion of each thawed aliquot was discarded as infectious biological material (IBM).

Peripheral blood mononuclear cell (PBMC) isolation

PBMCs were isolated from venous blood collected in sodium heparin tubes (BD vacutainer tubes, Franklin Lakes, NJ, USA). Within four hours of collection, PBMC isolation was conducted by density-gradient sedimentation of whole blood diluted at a 1:2 ratio in Roswell Park Memorial Institute medium (RPMI) 1640 (Lonza, Basel, Switzerland) at room-temperature. The diluted blood was layered over an appropriate volume of Lymphoprep (Axis-Shield, Dundee, UK) at room-temperature. Then, the PBMC were then recovered, cryopreserved in a medium consisting of 10% dimethyl sulfoxide (DMSO; Sigma Aldrich, St. Louis, MO, USA) and 90% heat-inactivated fetal bovine serum (FBS; GIBCO, California, USA), and stored at -80 °C until use. For T-cell assays, the thawing process involved warming frozen cryovials at 37 °C in a water bath, and cells were resuspended in 5 mL of CTS OpTmizer (GIBCO, California, USA). After a wash with OpTmizer, cells were counted using a Neubauer chamber, and the viability was assessed by trypan blue; cells were resuspended in OpTmizer medium to a density of 4 x 10⁶ cells/mL.

The subunit 1 of the spike protein of SARS-CoV-2 (RayBiotech, Peachtree Corners, Georgia, USA) was selected as the primary antigen due to its display of the most immunogenic epitopes of the spike protein. Additionally, it contains the receptor binding domain (RBD) fragment of the virus, which mediates binding to the host receptor angiotensin-converting enzyme 2 (ACE2) in lung cells.

SARS-CoV-2 detection

Sample processing was conducted through nucleic acid extraction, followed by one-step real-time RT-PCR amplification and detection for SARS-CoV-2. A Roche Magnapure instrument (Roche Diagnostics, Basel, Switzerland) was used for viral RNA extraction, and the following ModularDx kits (TIB Molbiol, Berlin, Germany) were employed:

• 53-0775-96 Sarbeco N-gene detects SARS and SARS-CoV-2

• 53-0776-96 Sarbeco E-gene detects SARS and SARS-CoV-2

• 53-0777-96 SARS-CoV-2 RdRP detects SARS-CoV-2

Determination of IgG anti-SARS-CoV-2 binding antibodies

For the determination of total anti-SARS-CoV-2 serum antibodies, a semi-quantitative enzyme-linked immunosorbent assay (ELISA) was employed to detect IgG antibodies to the spike protein subunit 1 domain (ELISA anti-SARS-CoV-2 (IgG); Catalog # 2606-9601 G; EUROIMMUN, Lübeck, Germany). Samples were processed according to the manufacturer’s instructions and analyzed on the EUROIMMUN Analyzer I (EUROIMMUN, Lübeck, Germany). Results are reported semi-quantitatively in ELISA ratio, representing a measure of the relative antibody concentration in participants’ serum. For the calculation of the relative concentration, the ratio of the extinction value of the control or sample to the extinction value of the calibrator was determined using the following formula: relative concentration (ratio) = (extinction of control or volunteer sample) / (extinction of calibrator).

Interpretation of results, in terms of positivity, was conducted according to the manufacturer’s instructions:

• Ratio <0.80: Negative

• Ratio >0.8 to <1.1: Uncertain

• Ratio >1.1: Positive

To estimate the geometric mean titers (GMT) of the IgG anti-spike subunit 1 antibodies in participants’ serum, serial dilutions (1:100, 1:300, 1:900, 1:2700, 1:5400) were performed for all serum samples with ratio values equal to or greater than 1.1 at the 1:100 dilution. For sera with ratio values < 0.8 at the 1:100 dilution, a titer of 1:20 was assigned for simplified analysis.

Pseudovirus neutralization assay

The presence of neutralizing antibodies was assessed using a microneutralization assay. The assay relies on the inhibition capacity of infection in an in vitro model present in serum samples and employed recombinant vesicular stomatitis virus (rVSV) pseudovirus particles expressing the protein from the ancestral Wuhan-1 strain, Alpha, Delta, Beta, and the Omicron subvariants BA.2 (clone 1) and BA.5 (clone 4) (VSV-eGFP-SARS2) kindly provided by Dr. Sean Whelan (Washington University, USA). The cellular model used to assess the inhibition capacity was the Vero E6 cell line (The American Type Culture Collection (ATCC) CRL-1586, Manassas, VA, USA), which is susceptible to infection as it expresses the recognition receptors for the SARS-CoV-2 spike protein.

Before performing the assay (previously validated and established as an analytical method), all serum samples were inactivated at 56 °C for 30 minutes. In 96-well plates, 1.3 x 10⁴ Vero E6 cells (ATCC, Manassas, VA, USA) per well were seeded and incubated for 24 hours at 37 °C, 5% CO2, allowing them to reach 85% confluence. Next, serum samples were serially diluted 1:2 in FBS-free Eagle’s minimal essential medium (EMEM; Rahway, New Jersey, USA) in duplicate, starting with a 1:20 dilution up to 1:1280. Diluted samples were mixed with the concentration of particles of VSV-SARS-CoV-2 S pseudoviruses from the ancestral strain and the aforementioned variants, capable of causing cellular damage at 50% (50% tissue culture infectious dose, TCID50). The mixture was incubated for 60 minutes at 37 °C, 5% CO2. Then, each serum dilution was transferred to a parallel plate containing Vero E6 cells and incubated for 72 h at 37 °C, 5% CO2.

After the incubation period, 3.7% formaldehyde was added and incubated for 30-40 minutes at room temperature. The plates were washed twice with PBS, and the recording and analysis of the plates was carried out by optical microscopy, documenting the presence or absence of damage to the monolayer, known as cytopathic effect, at each dilution of the different serum samples. These values were used to calculate the 50% protection level by applying the Spearman-Karber Method, obtaining the 50% inhibitory dilution (ID50) and the protective titer of each sample. The upper and lower detection limits for neutralizing activity are ID50 > 1.6 and a titer > 1:40 (initial dilution). Each assay included negative and positive infection controls (uninfected cells and infection control inoculated with the reporter vector VSV-eGFP-SARS2 and the subvariants in a suspension containing 100 TCID50). Titers < 1:40 (initial dilution) are reported with a value of 20 for statistical analysis.

Evaluation of cytokines in cell culture supernatants

PBMCs were resuspended at a concentration of 2 x 10⁶ cells/mL in CTS OpTmizer medium (GIBCO, California, USA). Duplicate samples of 2 x 10⁵ cells/well were plated in 96-well plates and stimulated with 5 µg/mL of the spike protein subunit 1 (RayBiotech, Peachtree Corners, GA), using culture medium as a negative control. After 18 hours of culture, the supernatant was collected, aliquoted, and stored at -20 °C until use for cytokine determination. Subsequently, the supernatants were thawed and centrifuged at 14,000 rpm for 10 minutes, and cytokine concentrations were measured using the Th1/Th2 Bio-Plex kit (BIO-RAD, California, USA). This kit allows the quantification using the Bio-Plex 200 system and Bio-Plex Manager 6.1 software (BIO-RAD, California, USA). Values were extrapolated from a concentration curve and expressed in pg/mL.

Hemagglutination inhibition antibody assay for Newcastle disease virus (NDV)

A hemagglutination inhibition assay was performed to assess the presence of inhibitory antibodies against specific hemagglutination of NDV. This method, adapted from the original avian sera procedure, was implemented and validated in our group for human serum analysis. The procedure utilized a system with 1% avian erythrocytes and eight hemagglutinant units (8 HAU/mL) of inactivated NDV antigen (AgNDV, DCV Inc. Lot: 23920103). Briefly, serum samples were inactivated for 30 minutes at 56 °C; 100 µL of each sample underwent pre-absorption with an equal volume of a 5% avian erythrocyte suspension and incubated overnight (16-18 h) at 2-8 °C. Next, the samples were centrifuged at 1,500 x g for 60 seconds, and the supernatants were collected and stored at -20 °C until use.

In 96-well round-bottom plates, 25 µL/well of pre-absorbed serum samples were placed in duplicate, and serial 1:2 dilutions were made (starting with a 1:8 dilution, subsequent dilutions included 1:16, 1:32, 1:64, 1:128, 1:256, 1:512, and 1:1,024). Subsequently, 25 µL/well of AgNDV suspension adjusted to 8 HAU/mL was added, and the samples were incubated (inhibition process) for 30 minutes at room-temperature (19-25 °C). Then, 25 µL of 1% avian erythrocyte suspension was added and incubated for 40 minutes at room temperature (19-25 °C). The interpretation of the plates was performed by placing them at a 45° position to observe the precipitated erythrocytes flowing (teardrop formation). The technique’s limit of detection was a titer of 1:4, and the positive cutoff limit started from the titer of 1:8. Samples that did not show inhibitory activity or whose activity was below the 1:4 dilution were assigned the value of the 1:2 dilution, corresponding to the immediately preceding dilution (15,16).

Statistical analysis

To outline the demographic characteristics of the study population, measures of central tendency and dispersion were utilized for continuous variables, while proportions were employed for discrete or categorical variables. Continuous variables underwent analysis using one-way ANOVA and students’ t-tests, whereas non-parametric tests were applied to discrete variables.

For safety assessments, the z-test was employed to compare proportions between treatment groups in the context of vaccine versus placebo, and the chi-square test was used for comparisons involving administration routes, vaccine, or placebo.

Individual antibody titers were quantified as the highest dilution titer that elicited a positive signal. Concurrently, the T-cell response was assessed by determining the concentration of cytokine-producing cells after stimulation with the spike subunit 1 protein following an 18-hour incubation period. The population results were characterized by a geometric mean (GM) and a 95% confidence interval.

Safety after vaccination with AVX/COVID-12

AEs were documented in subjects receiving IM AVX/COVID-12 (n=41), IM placebo (n=40), IN AVX/COVID-12 (n=40), and IN placebo (n=37) (total subjects 158). At day 28, IM and IN placebo group subjects received the AZ/ChAdOx-1-S vaccine, and AEs were recorded (n=71). Therefore, AEs were documented for 158 subjects receiving IM or IN AVX/COVID-12 vaccine and placebo groups, in addition to 71 subjects from the IM and IN placebo group who received the AZ/ChAdOx-1-S vaccine, making a total of 229 subjects (Tables 1S).

From the 229 subjects analyzed, 186 subjects reported AEs, with 38 belonging to the group that received the AVX/COVID-12 vaccine IM and 31 from the IM placebo group. Furthermore, 36 individuals came from the group that received the AVX/COVID-12 vaccine IN, and 29 subjects received the IN placebo. Considering the number of subjects recruited for each group that received the vaccine IM administration (vaccine or placebo), it was observed that 92.68% of participants who received the AVX/COVID-12 vaccine reported AEs, while the percentage for the IM placebo group was 77.5%. This difference in proportions for both groups was statistically significant, with a higher proportion of affected subjects in the AVX/COVID-12 vaccine group (Figure 2A). Analyzing the groups that received the AVX/COVID-12 vaccine and placebo IN, it was observed that 90% and 78.37% of subjects in these groups reported adverse events, respectively. The difference between these proportions was not statistically significant (Figure 2A).

• Download figure
• Open in new tab

Figure 2. Adverse events 7 days after vaccination with AVX/COVID-12 or AZ/ChAdOx-1-S.

Adverse events in participants following vaccination with the AVX/COVID-12 vaccine, compared with the AZ/ChAdOx-1-S vaccinated and placebo group. A) Percentage of participants affected by adverse events classified by severity; B) Local adverse events of special interest; C) Systemic adverse events of special interest; and D) Adverse events potentially associated with the vaccine. p-value calculated from a comparison of proportions (Z-test). Statistically significant differences were observed with p-values: p≤0.05.

After completing the follow-up period and unblinding the study, subjects initially receiving the placebo were administered a booster with the AZ/ChAdOx-1-S vaccine. The proportion of subjects reporting any AEs in the group that received the AVX/COVID-12 vaccine was significantly higher than the group that received the AZ/ChAdOx-1-S vaccine (Figure 2A). No significant differences were observed in the proportions of both groups when AEs were analyzed and grouped by severity.

Special interest local AEs reported at 7 days post-immunization, categorized by the number of affected subjects, were recorded (Table 2S). About, 19.21% of the study participants reported being affected by at least one of these events. Specifically, for each study group, this corresponds to 41.46% for the AVX/COVID-12 IM group, 15% for the IM placebo group, 17.5% for the AVX/COVID-12 IN group, 5.4% for the IN placebo group, and 16.9% for the AZ/ChAdOx-1-S group. When comparing the proportion of subjects affected by the total events (Table 2S), it was observed that AVX/COVID-12 IM had a significantly higher proportion than IM placebo (p=0.008) and AZ/ChAdOx-1S vaccine (p=0.004). This pattern was also observed for mild events, while for moderate and severe events, no statistically significant differences were found among these groups (Table 2S).

We identified statistically significant differences in AEs related to local general disorders and administration site conditions when comparing the group receiving AVX/COVID-12 IM with the AZ/ChAdOx-1-S vaccine group (p=0.001). Additionally, when the AVX/COVID-12 vaccinated group was compared with the placebo group, statistically significant differences were also observed (p=0.003) (Figure 2B). General discomfort included symptoms such as injection site pain (Table 2S).

Similarly, we analyzed systemic AEs of special interest reported within 7 days after the administration of the AVX/COVID-12 vaccine. About, 44.1% of the study participants reported being affected by one of these events. Specifically, 58.53% corresponded to the IM AVX/COVID-12 group, 50% to the IM placebo group, 57.5% to the IN AVX/COVID-12 group, 40.54% to the IN placebo group, and 26.76% to the AZ/ChAdOx-1-S group (Table 3S). When comparing groups, it was observed that the group receiving IM AVX/COVID-12 had a significantly higher proportion of subjects affected by this type of event than the AZ/ChAdOx-1-S group (p=0.0009). Analyzing events according to severity, a significant difference was found for mild events (Table 3S).

Subsequently, an analysis of events classified by system organ class (SOC) and preferred term (PT) for systemic AEs at 7 days post-immunization was performed (Table 3S). This analysis shows that the group receiving IM AVX/COVID-12 had a significantly higher proportion of subjects affected than the AZ/ChAdOx-1-S group for mild disorders of the nervous system, particularly headache (p=0.006); mild gastrointestinal disorders, particularly odynophagia (p=0.01); and mild thoracic and mediastinal respiratory disorders, particularly rhinorrhea (p=0.0009) (Figure 2C and Table 3S).

In the comparison between IM AVX/COVID-12 and placebo, a statistically significant difference was observed in the proportion of subjects affected by general disorders and site administration alterations (p=0.05). When the AVX/COVID-12 vaccine was administered IN, a significantly higher proportion of subjects showed mild gastrointestinal disorders compared to the IN placebo group (p=0.03) (Figure 2C).

Finally, regarding AEs related to vaccination, 9.17% of subjects reported AEs (Table 4S). In particular, 14.63% of subjects in the IM AVX/COVID-12 group, 10% in the IM placebo group, 7.5% in the IN AVX/COVID-12 group, 2.7% in the IN placebo group, and 9.85% in the AZ/ChAdOx-1-S group were reported. When analyzing events by SOC and PT, no statistically significant differences were observed despite variations in the proportion of subjects affected (Figure 2D).

AVX/COVID-12 induced binding and neutralizing antibody titers against Wuhan-1 and SARS-CoV-2 variants of concern

The evaluation of antibody titers and their neutralizing capacity in sera from AVX/COVID-12 vaccinated volunteers against the spike protein was conducted using ELISA and the pseudovirus neutralization assay at 14 days post-immunization, both for the total number of volunteers vaccinated with AVX/COVID-12 IM and for subjects who did not develop COVID-19 during the initial 14 days of the study (Table 3). Subsequent assessments were carried out over one year in IM-vaccinated subjects (Table 5S and 6S) and IN (Table 7S and 8S).

The antibody response was analyzed for a year following immunization with the AVX/COVID-12 vaccine via intramuscular and intranasal routes. Significant differences are observed at all time points for anti-spike IgG antibodies in vaccinated participants; titers increased at all analyzed time points compared to baseline levels (Figure 3A), with the highest levels observed on day 14 post-immunization, followed by a gradual decline. Interestingly, a slight increase is observed on day 365, possibly due to SARS-CoV-2 infections during participants’ follow-up. When analyzing the population, excluding those who developed mild COVID-19 during the study period (Figure 3B), a similar antibody kinetics was observed. Additionally, when analyzing IgG anti-S titers in volunteers vaccinated IN, a comparable pattern is observed when excluding subjects positive for COVID-19 (Figure 3B).

• Download figure
• Open in new tab

Figure 3. Intramuscular and intranasal administration of the AVX/COVID-12 vaccine resulted in comparable anti-spike IgG antibody titers.

Geometric means and confidence intervals of serum antibody titers post-vaccination with the AVX/COVID-12 vaccine were assessed A) intramuscularly (red circles) and intranasally (blue triangles) throughout the study and B) intramuscularly (red circles) and intranasally (blue triangles) in subjects where COVID-19 was not detected during the study follow-up period. P values were calculated by comparing the geometric means using the Wilcoxon signed-rank test with variables presented on a logarithmic scale.

AVX/COVID-12 induced a ≥ 4-fold increase in anti-spike IgG titers in 73.7% of the subjects receiving IM immunization when compared to placebo (10%) (p<0.0001). In contrast, individuals receiving the vaccine IN showed a ≥ 4-fold increase of 51.3%, compared to 16.2% in the placebo group (p=0.001) (Figure 4A). Similarly, 76.5% of subjects who did not experience COVID-19 in the first 14 days post-immunization and received IM AVX/COVID-12 showed a ≥ 4-fold increase compared to 0% in the placebo group (p<0.0001). Meanwhile, 48.6% of volunteers who received the vaccine IN exhibited a ≥ 4-fold increase compared to 7.1% in the placebo group (p<0.0001) (Figure 4B).

• Download figure
• Open in new tab

Figure 4. Proportion of subjects with a ≥4-fold increase in anti-spike IgG antibody titers.

(A) All enrolled study participants and (B) subjects where SARS-CoV-2 infection was not detected during the 14 days after vaccination. P values were calculated using Fisher’s exact test.

Subsequently, neutralizing antibody titers against SARS-CoV-2 Wuhan-1 and Alpha, Beta, Delta, and Omicron BA.2 and BA.5 VOCs were analyzed. For the IM-administered AVX/COVID-12 vaccine, statistically significant differences in the neutralizing antibody responses were observed when compared to the placebo in all cases (Figure 5 and Table 5S). In contrast, in subjects who received IN immunization with AVX/COVID-12, statistically significant differences in the neutralizing antibody responses were only observed for Wuhan-1 and Alpha (Figure 5). In the case of subjects who did not present COVID-19 in the first 14 days, all groups immunized IM or IN showed statistically significant differences in the neutralizing antibody responses when compared to the placebo group, except for the anti-BA.5 neutralizing responses in the IN immunized group (Figure 5 and Table 6S).

• Download figure
• Open in new tab

Figure 5. Comparison of neutralizing antibody titers against SARS-CoV-2 variants of concern (VOC) in subjects 14 days after receiving AVX/COVID-12 or placebo.

Geometric mean comparison of neutralizing antibody titers against Wuhan, Delta, Alpha, Beta, and Omicron (BA.2 and BA.5) VOCs in volunteers after 14 days of receiving AVX/COVID-12 intramuscular (IM) (closed red circles) or IM placebo (open red circles) and AVX/COVID-12 intranasal (IN) (closed blue triangles) or IN placebo (open blue triangles). Analysis was performed on the total of vaccinated individuals, regardless of SARS-CoV-2 infection confirmation (SARS-CoV-2 PCR+/-), or in subjects who did not test positive for SARS-CoV-2 in a PCR test (SARS-CoV-2 PCR Negatives). Mann–Whitney U test with variables presented on a natural logarithmic scale.

In addition, the proportion of subjects who exhibited a ≥ 2.5-fold increase in neutralizing antibody titers against Wuhan-1 and the aforementioned VOC was determined. For subjects who received AVX/COVID-12 IM immunization, the proportions of those exhibiting a ≥ 2.5-fold increase in neutralizing antibody titers range from 84.2% to 50% (Alpha > Wuhan-1 > Omicron BA.5 > Delta > Omicron BA.2 > Beta), compared with subjects who received IM placebo, where 35.9% to 12.8% exhibited a ≥ 2.5-fold increase in neutralizing antibody titers (p < 0.0001 to 0.003) (Figure 6A). For those vaccinated with AVX/COVID-12 IN, the percentage of individuals who exhibited a ≥ 2.5-fold increase in neutralizing antibody titers ranges from 82.1% to 35.9% (Wuhan-1 > Alpha > Omicron BA.5 > Beta > Omicron BA.2 > Delta) (p > 0.0001 to 0.045), except for the anti-BA.5 neutralizing antibody response, where no statistically significant differences with the placebo were observed (Figure 6A).

• Download figure
• Open in new tab

Figure 6. Proportion of subjects with a ≥2.5-fold increase in neutralizing titers against SARS-CoV-2 variants of concern induced by AVX/COVID-12 immunization.

Neutralizing antibody titers against Wuhan, Delta, Alpha, Beta, and Omicron (BA.2 and BA.5) variants of concern were measured 14 days after intramuscular (IM) (red closed bars) or intranasal (IN) (blue closed bars) AVX/COVID-12 administration, and IM (striped red bars) or IN (striped blue bars) placebo administration. A) In the total of vaccinated individuals, regardless of SARS-CoV-2 infection confirmation (SARS-CoV-2 PCR +/-) or B) in subjects who did not test positive for SARS-CoV-2 in a PCR test (SARS-CoV-2 PCR Negatives). P values were calculated using Fisher’s exact test.

In the sub-analysis, only subjects who did not present with COVID-19 in the first 14 days post-immunization were considered. For subjects who received AVX/COVID-12 IM, the percentage of those exhibiting a ≥ 2.5-fold increase in neutralizing antibody titers ranged from 85.3% to 44.1% (Alpha > Wuhan-1 > Omicron BA.5 > Delta > Omicron BA.2 > Beta), compared with volunteers administered a placebo, ranging from 35.9% to 12.8% (p > 0.0001 to 0.03). Among the group vaccinated IN, the percentage of individuals who exhibited a ≥2.5-fold increase in neutralizing antibody titers ranged from 81.1% to 32.4% (Wuhan-1 > Alpha > Omicron BA.5 > Beta > Omicron BA.2 > Delta). However, except for of the anti-BA.5 neutralizing antibody responses, no statistically significant difference was observed when compared with the placebo group (Figure 6B). Nevertheless, it should also be noted that the IN placebo control group presented an unusually higher rise of anti-BA.5 specific antibodies as compared to the other VOCs, perhaps indicative of a recent infection.

Comparable IFN-γ positive cellular responses were identified among participants immunized with AVX/COVID-12, regardless of the administration route

IFN-γ production was measured from supernatants of PBMCs obtained from volunteers vaccinated IM or IN (Tables 5 and 6) with the AVX/COVID-12 vaccine. Cells were collected on days 0, 14, 180, and 365 (Table 7) and stimulated in vitro with purified SARS-CoV-2 spike protein subunit 1 (Wuhan-1). In the total vaccinated individuals, regardless of SARS-CoV-2 infection and/or COVID-19 confirmation (SARS-CoV-2 PCR+/- and/or COVID-19+/-) (Table 7), statistically significant differences in IFN-γ production were observed at day 365 for IM-vaccinated individuals (p < 0.01) and at days 180 (p < 0.03) and 365 (p < 0.01) in IN-vaccinated individuals (Figure 7A).

• Download figure
• Open in new tab

Figure 7. Cellular responses induced by the AVX/COVID-12 Vaccine.

IFN-γ production was measured from peripheral blood mononuclear cells (PBMCs) of volunteers immunized intramuscularly (IM) with red circles or intranasally (IN) with blue triangles using the AVX/COVID-12 vaccine at the indicated time points. Volunteers’ PBMCs were stimulated for 18 hours with purified SARS-CoV-2 S1 protein (Wuhan-1), and IFN-γ production was measured from cell culture supernatants using BioPlex. A) In the total vaccinated individuals, regardless of SARS-CoV-2 infection and/or COVID-19 confirmation (SARS-CoV-2 PCR+/- and/or COVID-19+/-), or B) in subjects who did not test positive for SARS-CoV-2 in a PCR test and/or COVID-19 confirmation (SARS-CoV-2 PCR and/or COVID-19 Negative). Significant differences were calculated with the Wilcoxon signed-rank test.

Meanwhile, in subjects who did not test positive for SARS-CoV-2 in a PCR test and/or COVID-19 confirmation (SARS-CoV-2 PCR and/or COVID-19 negative) (Table 8), the response observed at day 365 was higher compared to the SARS-CoV-2 PCR+/- and/or COVID-19+/- group for both IM and IN immunized individuals. A trend towards increased IFN-γ concentration was evident in both IM and IN immunized groups with the AVX/COVID-12 vaccine; however, no statistically significant differences were observed (Figure 7B).

Immunization with the AVX/COVID-12 vaccine induces notably low specific antibody titers against the NDV vector

To assess the immune response elicited against the NDV vaccine vector, we evaluated the specific antibody titers exhibiting hemagglutination inhibition (HAI) activity in serum samples from individuals participating in phase I and II studies.

No antibodies with specific HAI against NDV were detected in all serum samples from individuals who participated in the phase II study on day 0 of recruitment, before the administration of the AVX/COVID-12 vaccine as a booster dose. Samples above the cut-off threshold of 8 HAI titers were considered positive. On day 14 following the initial administration of the AVX/COVID-12 vaccine, only two samples displayed titers above 8, indicating seroconversion. Meanwhile, on days 42 and 90, 4 and 3 out of 144 sera exhibited titers equal to or greater than 8, respectively. These results demonstrate that the administration of the AVX/COVID-12 vaccine at a dose of 10^8.0 EID50/dose via the IM route induces a low specific seroconversion to NDV (Figure 8).

• Download figure
• Open in new tab

Figure 8. Immunization with the AVX/COVID-12 vaccine induces notably low specific antibody titers against the NDV vector.

Analysis of hemagglutination inhibition antibody (HAI) titers specific to the Newcastle disease virus (NDV) vector in sera from individuals who received the AVX/COVID-12 vaccine as a booster dose in the phase II clinical trial (green circles, n=154) or as part of the primary immunization scheme with two doses on day 0 and a booster on day 21 (orange circles, n=10), and after a homologous booster dose on day 365 in the phase I clinical trial (red circles, n=43). Samples above the cut-off threshold of 8 HAI titers were considered positive (doted line).

In addition, serum samples from individuals participating in phase I, who received two doses of 10^8.0 EID50/dose of the AVX/COVID-12 vaccine, were analyzed. It was observed that all serum samples were negative for specific antibodies to the NDV vector before the first immunization via IN or IM administration. On day 14 after immunization, only 1 sample was positive. Meanwhile, titers higher than 8 were detected after the second application of the AVX/COVID-12 vaccine (Day 42). On the 90th day of follow-up, only 4 out of 10 sera showed titers higher than 8. After one year, volunteers received a third dose as a boost. Before boosting, only 6 volunteers had antibody titers equal to or greater than 8. After boosting, 42 out of 43 samples were positive, most showing low titers against NDV. Seroconversion slowly faded, and on day 90 after the boost, only 28 samples showed low antibody titers (Figure 8). Collectively, the data reveal that the induction of NDV-specific antibodies is exceedingly low (less than 0.2%) in the studied population after a single dose of the AVX/COVID-12 vaccine. Following the second and third immunizations, seroconversion increased; nevertheless, antibody titers remained at a low level. It is important to emphasize that the technique developed with highly sensitive.